Voluntis said today its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate Sanofi‘s (NYSE:SNY) Toujeo insulin glargine. The company’s software already works with Lantus and Levemir.
The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. The app gives real-time basal insulin dosing recommendations and educational coaching messages based on blood glucose levels to patients with Type II diabetes. The web portal enables healthcare practitioners to develop personalized treatment plans and track their patient population remotely.
The company said it is working on an extension for the app that would include all basal insulins and GLP-1 basal insulin combos.
Insulia launched in the U.S. this month and is slated to launch soon in the European market, according to Voluntis.
“We’re aiming to help people with Type II diabetes get to the right dose every day, whatever their insulin,” CEO Pierre Leurent said in prepared remarks. “We want to empower people with type 2 diabetes to better manage their condition through technology.”
